| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Antiviral; enteroviruse
cis-Resveratrol targets multiple cellular pathways including viral replication enzymes, sirtuins, and oxidative stress pathways. It inhibits enteroviruses with IC50s of 12.2 µM. The compound inhibits viral replication enzymes, supporting studies on natural phenolic antivirals. It enables analysis of sirtuin-mediated antiviral signaling. cis-Resveratrol also modulates signaling pathways related to oxidative stress and apoptosis, and has shown potential in cardiovascular and neuroprotective studies. |
|---|---|
| ln Vitro |
Three new compounds, (3S)-dihydrobonducellin 8-O-β-D-glucopyranoside (1), 3',5'-dimethoxy-jezonolid (2), and latisilinoid (3), along with 16 known compounds, were isolated from the twigs of Caesalpinia latisiliqua (Leguminosae). The known compounds were identified as flavonoids, stilbenes, and phenolics as determined by extensive spectroscopic methods, including 1D and 2D NMR. All the isolated compounds were evaluated for their antiviral activity in HRV1B-, CVB3-, and EV71-infected cells. Among the tested compounds, three flavonoids (4-6) and two stilbenes (12 and 14) exhibited significant antiviral activity. This is the first phytochemical investigation of C. latisiliqua twigs.[1]
cis-Resveratrol demonstrates significant in vitro antiviral activity, inhibiting enteroviruses with IC50s of 12.2 µM. It exhibits antioxidant, anti-inflammatory, and anticancer properties. The compound's activity is typically assessed in antiviral assays measuring viral replication inhibition, antioxidant assays (DPPH, ABTS), and anti-inflammatory assays measuring cytokine production. It plays a role in modulating signaling pathways related to oxidative stress and apoptosis. |
| ln Vivo |
In vivo studies for cis-Resveratrol have not been extensively documented in the available literature. As a naturally occurring polyphenolic compound, it has potential for in vivo applications in antiviral, antioxidant, and anti-inflammatory therapies. Studies in appropriate animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile. The compound has shown potential in cardiovascular and neuroprotective studies.
|
| Enzyme Assay |
Antiviral assay[1]
Antiviral activity was assayed by employing the SRB method using CPE reduction, as recently reported. To evaluate the activity, 3 × 104 cells per well of HeLa or Vero cells were seeded using MEM supplemented with 10% FBS and 0.01% antibiotic–antimycotic solution onto a 96-well culture plate and incubated for 24 h. After the medium was removed and cells were washed with 100 μL of phosphate buffered saline, the diluted virus suspension (0.09 ml), containing a 50% cell culture infective dose (CCID50) of the virus, was added to HeLa or Vero cells to produce the 50% CPE within 48 h after infection. Next, MEM containing 10 μM of the compounds (0.01 ml) was added and the culture plates were incubated at 37 °C in 5% CO2 for 2 days until 50% CPE was achieved. The 96-well plates were washed once with 200 μL of PBS. Ice-cold 70% acetone in water (100 μL) was added to each well and incubated for 30 min at −20 °C. After removing the 70% acetone, plates were dried in a drying oven at 55 °C for 30 min. Next, 0.4% (w/v) SRB in 1% acetic acid solution (100 μL) was added to each well and left for 30 min at room temperature. The SRB solution was then removed and the plates were washed five times with 1% acetic acid in water before oven-drying at 55 °C. Bound SRB was then solubilised with 10 mM unbuffered Tris-base solution (100 μL). After 30 min, the absorbance was read at 540 nm using a VersaMax microplate reader with a reference absorbance at 620 nm. The antiviral activity of each test compounds in HRV1B-, CVB3-, and EV71-infected cells was calculated as a percentage of the corresponding untreated control. For antiviral activity assays, cis-Resveratrol is tested against enteroviruses or other viruses at various concentrations. Viral replication is assessed by measuring viral RNA levels, plaque formation, or cytopathic effect. IC50 values are calculated from dose-response curves. For antioxidant assays, the compound is tested using DPPH, ABTS, or FRAP methods. For anti-inflammatory assays, cytokine production is measured by ELISA. |
| Cell Assay |
Cell culture[1]
The HRV1B, CVB3, and EV71 were obtained from the Division of Vaccine Research of the Korea Centers for Disease Control and Prevention and were propagated at 37 °C in Vero and 32 °C in HeLa cells. HRV1B was expanded in HeLa cells, while CVB3 and EV71 were expanded in Vero cells. These cells were maintained in minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS) and 0.01% antibiotic–antimycotic solution. The cells were incubated in MEM supplemented with 10% FBS and 0.01% antibiotic–antimycotic solution in a humidified atmosphere of 5% CO2 at 37 °C. Cells were detached using trypsin-EDTA. Five subsequent cycles of subculturing were performed before the cells were incubated with isolated compounds. For cellular studies, appropriate cell lines are cultured in appropriate media and treated with cis-Resveratrol at various concentrations. For antiviral studies, cells are infected with viruses and treated with the compound. Viral replication is assessed by qRT-PCR or plaque assays. For antioxidant studies, oxidative stress markers are measured using fluorescent probes. For anti-inflammatory studies, cytokine production is measured by ELISA. Cell viability is assessed using MTT assays. |
| Animal Protocol |
For in vivo efficacy studies, appropriate animal models of viral infection, inflammation, or oxidative stress would be used. cis-Resveratrol would be administered via oral or intraperitoneal routes at various doses. Viral load, inflammatory markers, or oxidative stress biomarkers would be measured. Pharmacokinetic parameters including half-life, clearance, and tissue distribution would be determined. However, detailed in vivo protocols for cis-Resveratrol have not been extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of cis-Resveratrol have not been fully characterized in the available literature. The compound has a molecular formula of C14H12O3 and a molecular weight of 228.24. Purity is ≥98% (may contain 1-5% trans). It is soluble in DMSO at 46 mg/mL. Powder should be stored at -20°C for 3 years or 4°C for 2 years. In solvent, it is stable for 6 months at -80°C or 1 month at -20°C.
|
| Toxicity/Toxicokinetics |
cis-Resveratrol is a research compound intended for laboratory use only and is not approved for human therapeutic use. As a naturally occurring polyphenolic compound, it exhibits antioxidant, anti-inflammatory, and anticancer properties. It has shown potential in cardiovascular and neuroprotective studies. Standard laboratory safety precautions should be followed when handling this compound. Storage at -20°C or 4°C is recommended.
|
| References | |
| Additional Infomation |
cis-resveratrol is the cis stereoisomer of resveratrol. (Z)-Resveratrol has been found in apple plants, Botrytis cinerea, and other organisms with relevant data. It is a stilbene nonflavonoid polyphenol produced by various plants, including grapes and blueberries. It possesses antioxidant, anti-inflammatory, cardioprotective, antimutagenic, and anticancer properties. Furthermore, it can inhibit platelet aggregation and the activity of various DNA helicases in vitro.
cis-Resveratrol is the cis-isomer of resveratrol with molecular formula C14H12O3 and molecular weight 228.24. It exhibits significant antiviral activity, inhibiting enteroviruses with IC50s of 12.2 µM, and has antioxidant, anti-inflammatory, and anticancer properties. The compound plays a role in modulating signaling pathways related to oxidative stress and apoptosis. It is for research use only and has not been approved for clinical applications. Purity ≥98% and storage at -20°C or 4°C is recommended. |
| Molecular Formula |
C14H12O3
|
|---|---|
| Molecular Weight |
228.24
|
| Exact Mass |
228.078
|
| Elemental Analysis |
C, 73.67; H, 5.30; O, 21.03
|
| CAS # |
61434-67-1
|
| Related CAS # |
Resveratrol;501-36-0
|
| PubChem CID |
1548910
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
449.1±14.0 °C at 760 mmHg
|
| Melting Point |
167-170ºC (dec)
|
| Flash Point |
222.3±14.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.763
|
| LogP |
3.14
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
246
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1/C=C\C2=CC(=CC(=C2)O)O)O
|
| InChi Key |
LUKBXSAWLPMMSZ-UPHRSURJSA-N
|
| InChi Code |
InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-
|
| Chemical Name |
5[(1Z)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol
|
| Synonyms |
cis-Resveratrol; cis-resveratrol; (Z)-resveratrol; 61434-67-1; Cis resveratrol; Resveratrol, (Z)-; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; cis-3,4',5-trihydroxystilbene; (Z)-Resveratrol;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (547.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (9.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (9.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3814 mL | 21.9068 mL | 43.8135 mL | |
| 5 mM | 0.8763 mL | 4.3814 mL | 8.7627 mL | |
| 10 mM | 0.4381 mL | 2.1907 mL | 4.3814 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
